DBPR108 Tablets in Type 2 Diabetes Mellitus Patients
Status:
Completed
Trial end date:
2019-06-28
Target enrollment:
Participant gender:
Summary
This study evaluate DRBP108 in the treatment of type 2 diabetes mellitus. The patients were
randomly allocated to four groups: 50 mg, 100 mg, 200 mg and placebo group.